ABOUT US

Sinntaxis was founded 2017 by scientists at Lund University and LU Holding AB. The company is managed by a team with vast experience in neuroscience/stroke research and pharmaceutical drug development and business development.

Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.

Sinntaxis has established a global network of Key Opinion Leaders ranging from experimental research to clinical trial in stroke recovery.

Research & development

Stroke is treated within hours after onset with removal of the obstructive clot in the brain vessels, but less than 10% of the stroke patients receive this therapy. There are no approved drugs that support rehabilitation and that enhance recovery of brain function after stroke. All stroke patients could be eligible for this treatment.

The Sinntaxis Approach

The graph shows improved restoration of brain function using therapy developed by Sinntaxis.

Employing mGlur5 inhibitors to restore brain function after stroke:

• mGluR5 activation is detrimental for recovery of lost brain functions after stroke

• mGluR5 inhibitors enhance recovery of lost brain functions

• mGluR5 inhibitors beneficially remodel brain connectivity by synaptic remodelling

• Start of treatment an extended period after brain insult is still effective

• Combined treatment of mGluR5 inhibitors with training synergistically enhances recovery

  Press release      

[2023-11-30]        

NEWS

Pre-clinical studies support Sinntaxis approach to restore lost neurological functions after stroke

Led by Sinntaxis’ founder, Prof Tadeusz Wieloch, the ground breaking study published in Brain shows improvement of brain function in mice and rats that were treated several days after experimental stroke with a class of substances called mGluR5 negative allosteric modulators (NAMs). This is the first time these substances have been shown to be linked to stroke recovery. Stroke causes damage that depresses brain circuitry and the article shows that this can be partially alleviated with the GluR5 NAM treatment. The article is a result of an international collaboration between Lund University, University of Rome La Sapienza and Washington University at St Louis.

Prof Wieloch, founder of Sinntaxis and lead author for the article comments: “This study shows promising results in mice and rats where they regained their somatosensory functions after mGluR5 NAM treatment. A temporary treatment effect was seen after just 30 minutes, but treatment for several weeks is needed to achieve a permanent effect. Improvement was seen even when the treatment was started 10 days after a stroke.”

https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awad293

“The study strongly supports Sinntaxis’ further development of mGluR5 NAMs as a drug candidate for stroke recovery, where the next step is a clinical proof of concept study. The  use of mGluR5 NAMs in stroke recovery is covered by IP owned by Sinntaxis AB.” says Tomas Eriksson, CEO of Sinntaxis.  

Sinntaxis receives important grant from Vinnova

Sinntaxis will receive SEK 900,000 from Vinnova’s call for proposals for “Innovative Startups step 2 autumn 2020” to continue to prepare for the planned clinical proof of concept trial. Stroke is one of the major public health challenges that annually afflicts 27,000 people in Sweden and 14 million worldwide. In Sweden alone, strokes cost society SEK 16 billion annually. Among survivors, one third suffer from lifelong disabilities that affect areas such as speech, thinking, memory and mobility. A new treatment that, combined with rehabilitation, improves the recovery of the brain following a stroke would entail significant improvement in the care of stroke patients and could reduce both the burden on relatives and the costs to society. The company’s drug candidate is based on a discovery made by Professor Tadeusz Wieloch and his research group at the Laboratory for Experimental Brain Research at Lund University. Professor Wieloch's group has recently shown in animal studies that treatment with molecules that block the glutamate receptor mGluR5 can significantly improve recovery of mobility, even when treatment is initiated several days after the stroke.

“We are extremely pleased and grateful for this Vinnova funding. It means that we can take important steps towards carrying out the planned clinical proof concept study with our drug candidate,” says Tomas Eriksson, CEO of Sinntaxis.

Tomas Eriksson appointed CEO of Sinntaxis AB

Tomas Eriksson is new CEO of the pharmaceutical company Sinntaxis from April 1, as current CEO Michael Oredsson will move from Sweden. Tomas Eriksson most recently comes from the CEO post at the listed company A1M Pharma. Sinntaxis is a portfolio company at LU Holding and a member of SmiLe Incubator in Lund

Read more here

MANAGEMENT & BOARD OF DIRECTORS

Contact Us

tw@sinntaxis.com

Stora Gråbrödersgatan 3A, 222 22, Lund                                                                  

CEO Tadeusz Wieloch
+46705129695